Clinical Trials Logo

Clinical Trial Summary

This study is a brief (3 month) longitudinal study following children between the ages of 4-16 years old who have been diagnosed with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). Parents and children (who are at a 2nd grade reading level) will complete questionnaires online or in person weekly for 3 months. Additionally, parents will track their child's symptoms 3 times/week using a mobile application for 3 months. The investigators are hoping to begin to characterize the longitudinal trajectory of neuropsychiatric symptoms in children with PANS. Additionally, the study will seek to identify baseline demographic and clinical characteristics (e.g., gender, recent onset versus chronic course, GAS versus other triggers) that predict severity of baseline neuropsychiatric symptoms and predict change in symptoms over time.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04382716
Study type Observational
Source University of Minnesota
Contact
Status Completed
Phase
Start date May 2, 2018
Completion date August 15, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04015596 - Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS Phase 4
Completed NCT01617083 - Antibiotic Treatment Trial for the PANDAS/PANS Phenotype Phase 2
Recruiting NCT02889016 - Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS N/A
Completed NCT02190292 - PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort
Withdrawn NCT01769027 - Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS Phase 2
Completed NCT01281969 - Intravenous Immunoglobulin for PANDAS Phase 3